21 Weinberg C R, Brown K G, Hoel D G. Altitude, radiation, and mortality from cancer and heart disease. Radiat Res, 1987, 112: 381-390
[2]
22 Huang Y, Du K M, Xue Z H, et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1alpha. Leukemia, 2003, 17: 2065-2073
[3]
23 Liu W, Guo M, Xu Y B, et al. Induction of tumor arrest and differentiation with prolonged survival by intermittent hypoxia in a mouse model of acute myeloid leukemia. Blood, 2006, 107: 698-707
[4]
24 Yan H, Peng Z G, Wu Y L, et al. Hypoxia-simulating agents and selective stimulation of arsenic trioxide-induced growth arrest and cell differentiation in acute promyelocytic leukemic cells. Haematologica, 2005, 90: 1607-1616
[5]
25 Li J, Xu Y, Long X D, et al. Cbx4 governs HIF-1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity. Cancer Cell, 2014, 25: 118-131
[6]
26 Han Y H, Xia L, Song L P, et al. Comparative proteomic analysis of hypoxia-treated and untreated human leukemic U937 cells. Proteomics, 2006, 6: 3262-3274
[7]
27 Liao S H, Zhao X Y, Han Y H, et al. Proteomics-based identification of two novel direct targets of hypoxia-inducible factor-1 and their potential roles in migration/invasion of cancer cells. Proteomics, 2009, 9: 3901-3912
[8]
28 Zhao X Y, Chen T T, Xia L, et al. Hypoxia inducible factor-1 mediates expression of galectin-1: the potential role in migration/invasion of colorectal cancer cells. Carcinogenesis, 2010, 31: 1367-1375
[9]
29 Jiang Y, Xue Z H, Shen W Z, et al. Desferrioxamine induces leukemic cell differentiation potentially by hypoxia-inducible factor-1 alpha that augments transcriptional activity of CCAAT/enhancer-binding protein-alpha. Leukemia, 2005, 19: 1239-1247
[10]
30 Xue Z H, Jiang Y, Yu Y, et al. Metavanadate suppresses desferrioxamine-induced leukemic cell differentiation with reduced hypoxia-inducible factor-1alpha protein. Biochem Biophys Res Commun, 2005, 332: 1140-1145
[11]
31 Zhang J, Song L P, Huang Y, et al. Accumulation of hypoxia-inducible factor-1 alpha protein and its role in the differentiation of myeloid leukemic cells induced by all-trans retinoic acid. Haematologica, 2008, 93: 1480-1487
[12]
32 Song L P, Zhang J, Wu S F, et al. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Oncogene, 2008, 27: 519-527
[13]
33 Peng Z G, Zhou M Y, Huang Y, et al. Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1alpha. Oncogene, 2008, 27: 839-847
[14]
34 Janardhan H P. The HIF-1 alpha-C/EBP alpha axis. Sci Signal, 2008, 1: jc2
[15]
35 Zhang J, Chen G Q. Hypoxia-HIF-1alpha-C/EBPalpha/Runx1 signaling in leukemic cell differentiation. Pathophysiology, 2009, 16: 297-303
[16]
36 He M, Wang Q Y, Yin Q Q, et al. HIF-1alpha downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation. Cell Death Differ, 2013, 20: 408-418
[17]
37 Kim J S, Cho E W, Chung H W, et al. Effects of Tiron, 4, 5-dihydroxy-1, 3-benzene disulfonic acid, on human promyelotic HL-60 leukemia cell differentiation and death. Toxicology, 2006, 223: 36-45
[18]
38 Abdel-Wahab O, Levine R L. Metabolism and the leukemic stem cell. J Exp Med, 2010, 207: 677-680
[19]
39 Callens C, Coulon S, Naudin J, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med, 2010, 207: 731-750
[20]
40 Krall A S, Christofk H R. Cancer: a metabolic metamorphosis. Nature, 2013, 496: 38-40
[21]
41 Losman J A, Looper R E, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science, 2013, 339: 1621-1625
[22]
42 Ye D, Ma S, Xiong Y, et al. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell, 2013, 23: 274-276
[23]
43 Losman J A, Kaelin W G Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev, 2013, 27: 836-852
[24]
19 Chen G Q, Shi X G, Tang W, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia(APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood, 1997, 89: 3345-3353
[25]
20 Eckhoff N D, Shultis J K, Clack R W, et al. Correlation of leukemia mortality rates with altitude in the United States. Health Phys, 1974, 27: 377-380
[26]
1 Cai X, Shen Y L, Zhu Q, et al. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia, 2000, 14: 262-270
[27]
2 Hu J, Liu Y F, Wu C F, et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2009, 106: 3342-3347
[28]
3 Shen Z X, Chen G Q, Ni J H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89: 3354-3360
[29]
4 Shen Z X, Shi Z Z, Fang J, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA, 2004, 101: 5328-5335
[30]
5 Huang M E, Ye Y C, Chen S R, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood, 1988, 72: 567-572
[31]
6 Gu Z M, Wu Y L, Zhou M Y, et al. Pharicin B stabilizes retinoic acid receptor-alpha and presents synergistic differentiation induction with ATRA in myeloid leukemic cells. Blood, 2010, 116: 5289-5297
[32]
7 Xu H Z, Huang Y, Wu Y L, et al. Pharicin A, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic catastrophe of cancer cells by interfering with BubR1 function. Cell Cycle, 2010, 9: 2897-2907
[33]
8 Liu C X, Yin Q Q, Zhou H C, et al. Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol, 2012, 8: 486-493
[34]
9 Liu C X, Zhou H C, Yin Q Q, et al. Targeting peroxiredoxins against leukemia. Exp Cell Res, 2012, 319: 170-176
[35]
10 Ziegler S, Pries V, Hedberg C, et al. Target identification for small bioactive molecules: finding the needle in the haystack. Angew Chem Int Ed Engl, 2013, 52: 2744-2792
[36]
11 Zhao K W, Li D, Zhao Q, et al. Interferon-alpha-induced expression of phospholipid scramblase 1 through STAT1 requires the sequential activation of protein kinase Cdelta and JNK. J Biol Chem, 2005, 280: 42707-42714
[37]
12 Zhao K W, Li X, Zhao Q, et al. Protein kinase Cdelta mediates retinoic acid and phorbol myristate acetate-induced phospholipid scramblase 1 gene expression: its role in leukemic cell differentiation. Blood, 2004, 104: 3731-3738
[38]
13 Huang Y, Zhao Q, Chen G Q. Phospholipid scramblase 1. Sheng Li Xue Bao, 2006, 58: 501-510
[39]
14 Huang Y, Zhao Q, Zhou C X, et al. Antileukemic roles of human phospholipid scramblase 1 gene, evidence from inducible PLSCR1-expressing leukemic cells. Oncogene, 2006, 25: 6618-6627
[40]
15 Chen G Q, Zhu J, Shi X G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide(As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood, 1996, 88: 1052-1061
[41]
16 Cai X, Yu Y, Huang Y, et al. Arsenic trioxide-induced mitotic arrest and apoptosis in acute promyelocytic leukemia cells. Leukemia, 2003, 17: 1333-1337
[42]
17 Zhu X H, Shen Y L, Jing Y K, et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst, 1999, 91: 772-778
[43]
18 Chen G Q, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res, 2003, 63: 1853-1859
